Get the Stockscreener App
208.95
2.31%
4.71
After Hours:
208.95
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $208.95, with a volume of 189.22K.
It is up +2.31% in the last 24 hours and up +5.35% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$204.24
Open:
$204.85
24h Volume:
189.22K
Relative Volume:
0.91
Market Cap:
$4.11B
Revenue:
$152.42M
Net Income/Loss:
$45.24M
P/E Ratio:
83.25
EPS:
2.51
Net Cash Flow:
$6.97M
1W Performance:
+9.17%
1M Performance:
+5.35%
6M Performance:
+24.57%
1Y Performance:
+81.29%
1-Day Range:
$198.37
$209.23
1-Week Range:
$178.72
$209.23
52-Week Range:
$93.58
$212.49
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
208.95 | 4.02B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Citigroup | Buy |
| Apr-10-25 | Initiated | Stifel | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Ligand Pharmaceuticals (LGND) Is Up 8.1% After Swinging to Profit and Filing New Equity ShelfWhat's Changed - simplywall.st
[144] LIGAND PHARMACEUTICALS INC SEC Filing - Stock Titan
Ligand plans three March investor appearances in Miami, Dana Point, NYC - Stock Titan
Ligand Pharma (LGND) Earnings Call Transcript - AOL.com
Ligand Pharmaceuticals (LGND): Investor Outlook With 20.74% Potential Upside - DirectorsTalk Interviews
LGND: 2025 Results & Focus on Qtorin - Yahoo Finance
Ligand Pharmaceuticals (LGND) Is Up 7.8% After Swing to Profit and New ATM Offering Filed – Has The Bull Case Changed? - Yahoo Finance
Expert Outlook: Ligand Pharmaceuticals Through The Eyes Of 5 Analysts - Sahm
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
LGND Should I Buy - Intellectia AI
Decoding Ligand Pharmaceuticals Inc (LGND): A Strategic SWOT Ins - GuruFocus
Ligand Pharmaceuticals Files For Mixed Shelf Offering - TradingView
Ligand Pharmaceuticals (NASDAQ: LGND) files S-3 for $100M ATM offering with Leerink - Stock Titan
LIGAND PHARMACEUTICALS INC SEC 10-K Report - TradingView
Oppenheimer Raises Price Target for LGND, Maintains Outperform R - GuruFocus
Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $277 From $275, Maintains Outperform Rating - marketscreener.com
Vanguard Group Inc. Has $367.79 Million Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Oppenheimer raises Ligand Pharma stock price target on royalty outlook By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (NASDAQ:LGND) Announces Quarterly Earnings Results, Beats Expectations By $0.56 EPS - MarketBeat
Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript Summary - 富途牛牛
Ligand Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Ligand Pharmaceuticals Inc (LGND) Q4 2025 Earnings Call Highligh - GuruFocus
Ligand Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Operating cash flow per share of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
Ligand Pharmaceuticals Incorporated Reiterates Earnings Guidance for the Year 2026 - marketscreener.com
Ligand Pharmaceuticals Q4 Adjusted Net Income, Revenue Rise; Reaffirms 2026 Guidance - marketscreener.com
Ligand Pharmaceuticals (NASDAQ:LGND) Updates FY 2026 Earnings Guidance - MarketBeat
Ligand (LGND) Surpasses Q4 Revenue Expectations with Robust Perf - GuruFocus
(LGND) Ligand Pharmaceuticals Expects 2026 Total Revenue Range $245M-$285M, vs. FactSet Est of $265.7M - marketscreener.com
(LGND) Ligand Pharmaceuticals Expects 2026 Adjusted EPS Range $8.00-$9.00, vs. FactSet Est of $8.42 - marketscreener.com
Ligand: Q4 Financial Results Overview - Bitget
Earnings Flash (LGND) Ligand Pharmaceuticals Incorporated Reports Q4 Revenue $59.7M, vs. FactSet Est of $55.6M - marketscreener.com
Earnings Flash (LGND) Ligand Pharmaceuticals Incorporated Posts Q4 Adjusted EPS $2.02 per Share, vs. FactSet Est of $1.50 - marketscreener.com
Ligand Pharmaceuticals Reports Strong Q4 and Full Year 2025 Financial Results - TradingView
Ligand Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
BRIEF-Ligand Pharmaceuticals Q4 EPS USD 2.12 - TradingView
Pharma group Ligand swings from loss to $124M profit as royalties jump - Stock Titan
Total debt per share of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
H.C. Wainwright Maintained Buy on Ligand (LGND) Feb 24, 2026 - Meyka
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $239.00 at HC Wainwright - Defense World
Net current asset value per share of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Operating cash flow per share of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Free cash flow per share of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Total debt per share of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $239.00 - MarketBeat
LGND Analyst Rating Update: HC Wainwright & Co. Raises Price Tar - GuruFocus
Ligand Pharmaceuticals IncorporatedEquity Right (LGNXZ) Price Target Increased by 68.71% to 0.00 - Nasdaq
State of New Jersey Common Pension Fund D Takes $2.40 Million Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals Incorporated $LGND Shares Bought by Envestnet Asset Management Inc. - Defense World
Volatility Watch: Is Ligand Pharmaceuticals Incorporated being accumulated by smart moneyPortfolio Gains Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):